The Alzheimer’s Therapeutics Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Large Number of Undiagnosed Patient Pool to Propel Growth
Residents who have been diagnosed with early-stage Alzheimer’s disease and some forms of dementia do not have adequate access to the healthcare system to fully diagnose and treat the condition. For instance, according to the 2021 World Alzheimer Report, only 46% of dementia patients and those who provide care recognised stigma and fear of a diagnosis as diagnostic hurdles. The market for Alzheimer’s medications is anticipated to expand due to the 10% underdiagnosis rate in low- and middle-income countries. The U.S. Food and Drug Administration (FDA) has already given its approval to a number of medication medications to help manage symptoms in Alzheimer’s patients. Aducanumab, a new drug that helps to reduce amyloid deposits in the brain and may slow the progression of Alzheimer’s, received accelerated approval from the FDA on June 7, 2021. However, it has not yet been demonstrated that it has an impact on clinical symptoms or outcomes, such as the progression of cognitive decline or dementia disease. On the other hand, the Alzheimer’s therapeutics business is struggling with a labour shortage that prevents it from meeting the rising demand for Parkinson’s and dementia medications. Over the projected period, it is anticipated that this factor will limit the market for Alzheimer’s therapeutics acceptance worldwide.
Increasing Occurrence of Alzheimer’s to Boost Market Growth
The market for Alzheimer’s disease medicines is anticipated to develop as the prevalence and incidence of the condition rise globally. The incidence of the disease rises due to an increasing senior population worldwide, which also presents a growth opportunity for the Alzheimer’s therapeutics industry. For example, the World Population Prospects (WPP), issued by the United Nations in 2021, estimates that 771 million people worldwide are 65 or older, which is three times the number in 1980. By 2030, the population is expected to increase by 3% annually, reaching 1.4 billion. As a result, these regions are prospective growth areas for the Alzheimer’s therapeutics market.
What Questions Should You Ask before Buying a Market Research Report?
• How is the Alzheimer’s Therapeutics market evolving?
• What is driving and restraining the Alzheimer’s Therapeutics market?
• How will each Alzheimer’s Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Alzheimer’s Therapeutics submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Alzheimer’s Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Alzheimer’s Therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of Alzheimer’s Therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Alzheimer’s Therapeutics market?
• Where is the Alzheimer’s Therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Alzheimer’s Therapeutics market today, and over the next 10 years:
• Our 196-page report provides 95 tables, 137 charts exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Alzheimer’s Therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Alzheimer’s Therapeutics prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Drug Type
• Donepezil
• Rivastigmine
• Memantine
• Galantamine
• Manufactured Combination of Memantine and Donepezil
Drug Class
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Manufactured Combination
Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 17 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Alzheimer’s Therapeutics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie, Inc.
• Amneal Pharmaceuticals Inc.
• Aurobindo Pharma Ltd
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd
• Eisai Co., Ltd.
• Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
• Lupin Ltd
• Macleods Pharmaceuticals Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Ltd., Inc.
• Torrent pharmaceuticals ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd
Overall world revenue for Alzheimer’s Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$2,870 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Alzheimer’s Therapeutics Market, 2022 to 2032 report help you?
In summary, our 190+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Alzheimer’s Therapeutics Market, 2022 to 2032 Market, with forecasts for drug type, drug class, and distribution channel, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 17 key national markets – See forecasts for the Alzheimer’s Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, South Korea, Australia and South Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Alzheimer’s Therapeutics Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Alzheimer’s Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Alzheimer’s Therapeutics Market Report 2022-2032: Forecasts by Drug (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine and Donepezil), by Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Manufactured Combination), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Alzheimer’s Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Occurrence of Alzheimer’s Disease to Drive Market Growth
3.2.1.2 Large Number of Undiagnosed Patient’s and Revised Diagnostic Guidelines to Propel Growth
3.2.2 Market Restraining Factors
3.2.2.1 Shortage of Skilled Medical Professionals
3.2.2.2 Lack of Proper Treatment Techniques
3.2.3 Market Opportunities
3.2.3.1 Surge in Number of Mergers and Acquisitions to Boost Market Growth
3.2.3.2 Increasing R&D Investments and Collaborations
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PESTLE Analysis
4 Alzheimer’s Therapeutics Market Analysis by Drug
4.1 Key Findings
4.2 Drug Segment: Market Attractiveness Index
4.3 Alzheimer’s Therapeutics Market Share by Drug, 2022 & 2032
4.4 Donepezil
4.4.1 Donepezil Market Forecast by Region, 2022-2032 (US$ Mn)
4.4.2 Donepezil Market Share by Region, 2022 & 2032 (%)
4.5 Rivastigmine
4.5.1 Rivastigmine Market Forecast by Region, 2022-2032 (US$ Mn)
4.5.2 Rivastigmine Market Share by Region, 2022 & 2032 (%)
4.6 Memantine
4.6.1 Memantine Market Share by Region, 2022 & 2032 (%)
4.6.2 Memantine Market Share by Region, 2022 & 2032 (%)
4.7 Galantamine
4.7.1 Galantamine Market Forecast by Region, 2022-2032 (US$ Mn)
4.7.2 Galantamine Market Share by Region, 2022 & 2032 (%)
4.8 Manufactured Combination of Memantine and Donepezil
4.8.1 Manufactured Combination of Memantine and Donepezil Market Forecast by Region, 2022-2032 (US$ Mn)
4.8.2 Manufactured Combination of Memantine and Donepezil Market Share by Region, 2022 & 2032 (%)
5 Alzheimer’s Therapeutics Market Analysis by Drug Class
5.1 Key Findings
5.2 Drug Class Segment: Market Attractiveness Index
5.3 Alzheimer’s Therapeutics Market Share by Drug Class, 2022 & 2032
5.4 Cholinesterase Inhibitors
5.4.1 Cholinesterase Inhibitors Market Forecast by Region, 2022-2032 (US$ Mn)
5.4.2 Cholinesterase Inhibitors Market Share by Region, 2022 & 2032 (%)
5.5 NMDA Receptor Antagonists
5.5.1 NMDA Receptor Antagonists Market Forecast by Region, 2022-2032 (US$ Mn)
5.5.2 NMDA Receptor Antagonists Market Share by Region, 2022 & 2032 (%)
5.6 Manufactured Combination
5.6.1 Manufactured Combination Market Forecast by Region, 2022-2032 (US$ Mn)
5.6.2 Manufactured Combination Market Share by Region, 2022 & 2032 (%)
6 Alzheimer’s Therapeutics Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment: Market Attractiveness Index
6.3 Alzheimer’s Therapeutics Market Share by Distribution Channel, 2022 & 2032
6.4 Hospital Pharmacies
6.4.1 Hospital Pharmacies Market Forecast by Region, 2022-2032 (US$ Mn)
6.4.2 Hospital Pharmacies Market Share by Region, 2022 & 2032 (%)
6.5 Retail Pharmacies
6.5.1 Retail Pharmacies Market Forecast by Region, 2022-2032 (US$ Mn)
6.5.2 Retail Pharmacies Market Share by Region, 2022 & 2032 (%)
6.6 Drug Stores
6.6.1 Drug Stores Market Forecast by Region, 2022-2032 (US$ Mn)
6.6.2 Drug Stores Market Share by Region, 2022 & 2032 (%)
6.7 Online Pharmacies
6.7.1 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ Mn)
6.7.2 Online Pharmacies by Region, 2022 & 2032 (%)
7 Alzheimer’s Therapeutics Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
8 North America Alzheimer’s Therapeutics Market Analysis
8.1 Key Findings
8.2 North America Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
8.3 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
8.4 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
8.5 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
8.6 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
8.7 U.S. Alzheimer’s Therapeutics Market Analysis
8.8 Canada Alzheimer’s Therapeutics Market Analysis
9 Europe Alzheimer’s Therapeutics Market Analysis
9.1 Key Findings
9.2 Europe Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
9.3 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
9.4 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
9.5 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
9.6 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
9.7 Germany Alzheimer’s Therapeutics Market Analysis
9.8 UK Alzheimer’s Therapeutics Market Analysis
9.9 France Alzheimer’s Therapeutics Market Analysis
9.10 Italy Alzheimer’s Therapeutics Market Analysis
9.11 Spain Alzheimer’s Therapeutics Market Analysis
9.12 Russia Alzheimer’s Therapeutics Market Analysis
9.13 Rest of Europe Alzheimer’s Therapeutics Market Analysis
10 Asia-Pacific Alzheimer’s Therapeutics Market Analysis
10.1 Key Findings
10.2 Asia-Pacific Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
10.3 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
10.4 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
10.5 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
10.6 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
10.7 Japan Alzheimer’s Therapeutics Market Analysis
10.8 China Alzheimer’s Therapeutics Market Analysis
10.9 India Alzheimer’s Therapeutics Market Analysis
10.10 Australia Alzheimer’s Therapeutics Market Analysis
10.11 South Korea Alzheimer’s Therapeutics Market Analysis
10.12 Rest of Asia Pacific Alzheimer’s Therapeutics Market Analysis
11 Latin America Alzheimer’s Therapeutics Market Analysis
11.1 Key Findings
11.2 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
11.3 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
11.4 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
11.5 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
11.6 Brazil Alzheimer’s Therapeutics Market Analysis
11.7 Mexico Alzheimer’s Therapeutics Market Analysis
11.8 Rest of Latin America Alzheimer’s Therapeutics Market Analysis
12 MEA Alzheimer’s Therapeutics Market Analysis
12.1 Key Findings
12.2 MEA Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
12.3 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
12.4 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
12.5 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
12.6 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
12.7 GCC Alzheimer’s Therapeutics Market Analysis
12.8 South Africa Alzheimer’s Therapeutics Market Analysis
12.9 Rest of MEA Alzheimer’s Therapeutics Market Analysis
13 Company Profiles
13.1 Company Share Analysis
13.2 AbbVie, Inc.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2017-2021
13.2.3.2 Regional Market Shares, 2021
13.2.3.3 Business Segment Market Shares, 2021
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Teva Pharmaceuticals Ltd., Inc.
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2017-2021
13.3.3.2 Regional Market Shares, 2021
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 Eisai Co., Ltd.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2017-2021
13.4.3.2 Regional Market Shares, 2020
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2017-2021
13.5.4 Product Benchmarking
13.6 Novartis AG
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2017-2021
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Zydus Lifesciences Ltd (CADILA)
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2017-2021
13.7.3.2 Business Market Shares, 2021
13.7.4 Product Benchmarking
13.8 Sun Pharmaceutical Industries Ltd.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2017-2021
13.8.4 Product Benchmarking
13.9 Dr. Reddy's Laboratories Ltd
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2017-2021
13.9.3.2 Regional Market Shares, 2021
13.9.3.3 Business Market Shares, 2021
13.9.4 Product Benchmarking
13.10 Aurobindo Pharma Ltd
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2017-2021
13.10.3.2 Business Market Shares, 2021
13.10.4 Product Benchmarking
13.11 Amneal Pharmaceuticals Inc.
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2017-2021
13.11.3.2 Business Market Shares, 2021
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 Macleods Pharmaceuticals Ltd.
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2018-2020
13.12.3.2 Regional Market Shares, 2020
13.12.3.3 Business Market Shares, 2020
13.12.4 Product Benchmarking
13.13 Viatris Inc.
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2017-2021
13.13.4 Product Benchmarking
13.14 Lupin Ltd
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2017-2021
13.14.3.2 Regional Market Shares, 2021
13.14.3.3 Business Market Shares, 2021
13.14.4 Product Benchmarking
13.15 Cipla Ltd.
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2017-2021
13.15.3.2 Business Market Shares, 2021
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook
13.16 Torrent pharmaceuticals ltd.
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Financial Analysis
13.16.3.1 Net Revenue, 2017-2021
13.16.4 Product Benchmarking
14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players
List of Tables
Table 1 Alzheimer’s Therapeutics Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
Table 2 Alzheimer’s Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): V” Shaped Recovery Scenario
Table 3 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery Scenario
Table 4 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery Scenario
Table 5 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery Scenario
Table 6 Donepezil Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 7 Rivastigmine Market Forecast by Region, 2022-2032 (US$ Million, AGR%, CAGR%)
Table 8 Memantine Market Forecast by Region, 2022-2032 (US$ Million, AGR%, CAGR%)
Table 9 Galantamine Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 10 Manufactured Combination of Memantine and Donepezil Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 11 Cholinesterase Inhibitors Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 12 NMDA Receptor Antagonists Market Forecast by Region, 2022-2032 (US$ Million, AGR%, CAGR%)
Table 13 Manufactured Combination Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 14 Hospital Pharmacies Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 15 Retail Pharmacies Market Forecast by Region, 2022-2032 (US$ Million, AGR%, CAGR%)
Table 16 Drug Stores Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 17 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 18 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 19 North America Alzheimer’s Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 20 North America Alzheimer’s Therapeutics Market Forecast by Drug, 2022-2032 (US$ million, AGR%, CAGR %)
Table 21 North America Alzheimer’s Therapeutics Market Forecast by Drug Class, 2022-2032 (US$ million, AGR%, CAGR%)
Table 22 North America Alzheimer’s Therapeutics Market Forecast by Distribution channel, 2022-2032 (US$ million, AGR%, CAGR%)
Table 23 U.S. Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 24 Canada Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 25 Europe Alzheimer’s Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 26 Europe Alzheimer’s Therapeutics Market Forecast by Drug, 2022-2032 (US$ million, AGR%, CAGR %)
Table 27 Europe Alzheimer’s Therapeutics Market Forecast by Drug Class, 2022-2032 (US$ million, AGR%, CAGR %)
Table 28 Europe Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR%)
Table 29 Germany Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 30 UK Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 31 France Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 32 Italy Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 33 Spain Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 34 Russia Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 35 Rest of Europe Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 36 Asia-Pacific Alzheimer’s Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 37 Asia-Pacific Alzheimer’s Therapeutics Market Forecast by Drug, 2022-2032 (US$ million, AGR%, CAGR %)
Table 38 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Drug Class, 2022-2032 (US$ million, AGR%, CAGR %)
Table 39 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 40 Japan Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 41 China Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 42 India Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 43 Australia Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 44 South Korea Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 45 Rest of Asia Pacific Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR %)
Table 46 Latin America Alzheimer’s Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR%)
Table 47 Latin America Alzheimer’s Therapeutics Market Forecast by Drug, 2022-2032 (US$ million, AGR%, CAGR %)
Table 48 Latin America Alzheimer’s Therapeutics Market Forecast by Drug Class, 2022-2032 (US$ million, AGR %)
Table 49 Latin America Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 50 Brazil Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 51 Mexico Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 52 Rest of Latin America Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 53 MEA Alzheimer’s Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 54 MEA Alzheimer’s Therapeutics Market Forecast by Drug, 2022-2032 (US$ million, AGR%, CAGR %)
Table 55 MEA Alzheimer’s Therapeutics Market Forecast by Drug Class, 2022-2032 (US$ million, AGR%, CAGR %)
Table 56 MEA Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 57 GCC Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 58 South Africa Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 59 Rest of MEA Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 60 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 61 AbbVie Inc.: Product Benchmarking
Table 62 AbbVie: Strategic Outlook
Table 63 Teva Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 Teva Pharmaceuticals Ltd.: Product Benchmarking
Table 65 Teva Pharmaceuticals Ltd.: Strategic Outlook
Table 66 Eisai Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 Eisai Co., Ltd.: Product Benchmarking
Table 68 Eisai Co., Ltd. Strategic Outlook
Table 69 Janssen Pharmaceuticals, Inc. (Johnson & Johnson): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Janssen Pharmaceuticals, Inc. (Johnson & Johnson): Product Benchmarking
Table 71 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 Novartis AG: Product Benchmarking
Table 73 Novartis AG: Strategic Outlook
Table 74 Zydus Lifesciences Ltd (CADILA): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Zydus Lifesciences Ltd (CADILA): Product Benchmarking
Table 76 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
Table 78 Dr. Reddy's Laboratories Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Dr. Reddy's Laboratories Ltd: Product Benchmarking
Table 80 Aurobindo Pharma Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Aurobindo Pharma Ltd: Product Benchmarking
Table 82 Amneal Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Amneal Pharmaceuticals Inc.: Product Benchmarking
Table 84 Amneal Pharmaceuticals Inc.: Strategic Outlook
Table 85 Macleods Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Macleods Pharmaceuticals Ltd.: Product Benchmarking
Table 87 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Viatris Inc.: Product Benchmarking
Table 89 Lupin Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Lupin Ltd: Product Benchmarking
Table 91 Cipla Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Cipla Ltd.: Product Benchmarking
Table 93 Cipla Ltd.: Strategic Outlook
Table 94 Torrent pharmaceuticals ltd. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Torrent pharmaceuticals ltd. Product Benchmarking
List of Figures
Figure 1 Alzheimer’s Therapeutics Market Segmentation
Figure 2 Alzheimer’s Therapeutics Market by Drug: Market Attractiveness Index
Figure 3 Alzheimer’s Therapeutics Market by Drug Class Segment: Market Attractiveness Index
Figure 4 Alzheimer’s Therapeutics Market by Distribution Channel: Market Attractiveness Index
Figure 5 Alzheimer’s Therapeutics Market: Market Dynamics
Figure 6 Global COVID Impact Analysis: Alzheimer’s Therapeutics Market Recovery Scenarios
Figure 7 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Alzheimer’s Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Alzheimer’s Therapeutics Market: Porter’s Five Forces Analysis
Figure 12 Alzheimer’s Therapeutics Market: PESTLE Analysis
Figure 13 Alzheimer’s Therapeutics Market Forecast by Drug 2022, 2027, 2032 (Revenue, CAGR%)
Figure 14 Alzheimer’s Therapeutics Market Share Forecast by Therapeutics, 2022, 2032 (%)
Figure 15 Donepezil Market Forecast by Region, 2022-2032 (US$ million)
Figure 16 Donepezil Market Share Forecast by Region, 2022 & 2032 (%)
Figure 17 Rivastigmine Market Forecast by Region, 2022-2032 (US$ million)
Figure 18 Rivastigmine Market Share Forecast by Region, 2022 & 2032 (%)
Figure 19 Memantine Market Share Forecast by Region, 2022 & 2032 (%)
Figure 20 Memantine Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 Galantamine Market Forecast by Region, 2022-2032 (US$ million)
Figure 22 Galantamine Market Share Forecast by Region, 2022 & 2032 (%)
Figure 23 Manufactured Combination of Memantine and Donepezil Market Forecast by Region, 2022-2032 (US$ million)
Figure 24 Manufactured Combination of Memantine and Donepezil Market Share Forecast by Region, 2022 & 2032 (%)
Figure 25 Alzheimer’s Therapeutics Market Forecast by Drug Class 2022, 2027, 2032 (Revenue, CAGR%)
Figure 26 Alzheimer’s Therapeutics Market Share Forecast by Drug Class, 2022, 2032 (%)
Figure 27 Cholinesterase Inhibitors Market Forecast by Region, 2022-2032 (US$ million)
Cholinesterase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 NMDA Receptor Antagonists Market Forecast by Region, 2022-2032 (US$ million)
Figure 29 NMDA Receptor Antagonists Market Share Forecast by Region, 2022 & 2032 (%)
Figure 30 Manufactured Combination Market Forecast by Region, 2022-2032 (US$ million)
Figure 31 Manufactured Combination Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 Alzheimer’s Therapeutics Market Forecast by Distribution Channel 2022, 2027, 2032 (Revenue, CAGR%)
Figure 33 Alzheimer’s Therapeutics Market Share Forecast by Therapeutics, 2022, 2032 (%)
Figure 34 Hospital Pharmacies Market Forecast by Region, 2022-2032 (US$ million)
Figure 35 Hospital Pharmacies Market Share Forecast by Region, 2022 & 2032 (%)
Figure 36 Retail Pharmacies Market Forecast by Region, 2022-2032 (US$ million)
Figure 37 Retail Pharmacies Market Share Forecast by Region, 2022 & 2032 (%)
Figure 38 Drug Stores Market Forecast by Region, 2022-2032 (US$ million)
Figure 39 Drug Stores Market Share Forecast by Region, 2022 & 2032 (%)
Figure 40 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ million)
Figure 41 Online Pharmacies Market Share Forecast by Region, 2022 & 2032 (%)
Figure 53 U.S. Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 54 Canada Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 64 Germany Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 65 UK Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 66 France Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 67 Italy Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 68 Spain Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 69 Russia Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 70 Rest of Europe Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 80 Japan Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 81 China Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 82 India Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 83 Australia Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 84 South Korea Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 85 Rest of Asia Pacific Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 94 Brazil Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 95 Mexico Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 96 Rest of Latin America Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 105 GCC Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 106 South Africa Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 107 Rest of MEA Alzheimer’s Therapeutics Market Forecast, 2022-2032 (US$ million, AGR %)
Figure 108 Alzheimer’s Therapeutics Market: Company Share Analysis, 2021
Figure 109 AbbVie Inc.: Net Revenue, 2017-2021 (US$ billion)
Figure 110 AbbVie Inc.: Regional Market Shares, 2021
Figure 111 AbbVie Inc.: Business Market Shares, 2021
Figure 112 Teva Pharmaceuticals Ltd.: Net Revenue, 2017-2021 (US$ million)
Figure 113 Teva Pharmaceuticals Ltd.: Regional Market Shares, 2021
Figure 114 Eisai Co., Ltd.: Net Revenue, 2017-2021 (US$ million)
Figure 115 Eisai Co., Ltd.: Regional Market Shares, 2021
Figure 116 Janssen Pharmaceuticals, Inc. (Johnson & Johnson): Net Revenue, 2017-2021 (US$ million)
Figure 117 Novartis AG: Net Revenue, 2017-2021 (US$ million)
Figure 118 Zydus Lifesciences Ltd (CADILA): Net Revenue, 2017-2021 (US$ million)
Figure 119 Zydus Lifesciences Ltd (CADILA): Business Market Shares, 2021
Figure 120 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2017-2021 (US$ Million)
Figure 121 Dr. Reddy's Laboratories Ltd: Net Revenue, 2017-2021 (US$ Million)
Figure 122 Dr. Reddy's Laboratories Ltd: Regional Market Shares, 2021
Figure 123 Dr. Reddy's Laboratories Ltd.: Business Market Shares, 2021
Figure 124 Aurobindo Pharma Ltd: Net Revenue, 2017-2021 (US$ million)
Figure 125 Aurobindo Pharma Ltd: Business Market Shares, 2021
Figure 126 Amneal Pharmaceuticals Inc.: Net Revenue, 2017-2021 (US$ ‘000’)
Figure 127 Amneal Pharmaceuticals Inc.: Business Market Shares, 2021
Figure 128 Macleods Pharmaceuticals Ltd.: Net Revenue, 2018-2020 (US$ million)
Figure 129 Macleods Pharmaceuticals Ltd.: Regional Market Shares, 2020
Figure 130 Macleods Pharmaceuticals Ltd.: Business Market Shares, 2020
Figure 131 Viatris Inc.: Net Revenue, 2017-2021 (US$ million)
Figure 132 Lupin Ltd: Net Revenue, 2017-2021 (US$ billion)
Figure 133 Lupin Ltd: Regional Market Shares, 2021
Figure 134 Lupin Ltd: Business Market Shares, 2021
Figure 135 Cipla Ltd.: Net Revenue, 2017-2021 (US$ million)
Figure 136 Cipla Ltd.: Business Market Shares, 2021
Figure 137 Torrent pharmaceuticals ltd.: Net Revenue, 2017-2021 (US$ million)
List of Companies Profiled in the Report
AbbVie, Inc.
Amneal Pharmaceuticals Inc.
Aurobindo Pharma Ltd
Cipla Ltd.
Dr. Reddy's Laboratories Ltd
Eisai Co., Ltd.
Janssen Pharmaceuticals, Inc.
Lupin Ltd
Macleods Pharmaceuticals Ltd.
Novartis AG
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Ltd., Inc.
Torrent pharmaceuticals ltd.
Viatris Inc.
Zydus Lifesciences Ltd
List of Other Companies Mentioned in the Report
Alembic Pharma Ltd.
Chongqing Zein
Finetech Pharma
Hikal Ltd.
Indena Ltd.
Ind-Swift Labs.
Jubilant Generics Inc.
Kolon Life Science
Macfarlan Smith (Johnson Matthey)
Megafine Pharma (P) Ltd.
Menovo
Neuland Labs
Pfizer Inc.
Piramal Healthcare Ltd.
PLIVA
Sanochemia Pharma Ltd.
Shandong Octagon Chemicals Limited
Sichuan Benepure Inc.
Unichem Labs
Vasudha Pharma Chem Ltd.
Wockhardt Ltd.
Zhejiang Huahai Pharma Ltd.
List of Associations Mentioned in the Report
Association of British Pharmaceutical Industry (ABPI)
Central Drugs Standard Control Organization (CDSCO)
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
European Commission
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Indian Drug Manufacturer's Association (IDMA)
International Society of Pharmaceutical Engineering (IPSE)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer's Association (KPMA)
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Industry and Information Technology (MIIT)
Pharmaceutical and Medical Devices Agency (PMDA)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
